外周血淋巴细胞/单核细胞比值对接受新药治疗的多发性骨髓瘤预后价值的研究

Abstract
Figure/Table
References (24)
Related Citation (6)

Download: PDF (633 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the prognostic value of the peripheral blood lymphocyte-to-monocyte ratio (LMR) on multiple myeloma (MM). Methods The overall survival of 100 MM patients who received new proteasome inhibitors and/or immunomodulatory drugs from January 2013 to January 2019 in the People′s Hospital of Ziyang, Sichuan Province was systematically reviewed, and the effect of LMR on prognosis was evaluated by the receiver operating characteristic curve (ROC) and other indicators. Results The area under the ROC curve was 0.612 and the corresponding optimal diagnostic threshold was 4.0, that was, the total survival time of MM patients with LMR≤4.0 was shorter than that of patients with LMR＞4.0. Conclusion LMR is a simple and economic indicator calculated by blood routine test results and provides a method to predict clinical outcomes in patients with MM who were treated with new agents.

Key words： Lymphocyte-to-monocyte ratio Multiple myeloma Receiver operating characteristic curve Prognostic value

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIAO Zhongting1 LI Juan1 LAN Xia1 HU Qiongying2

Cite this article:

LIAO Zhongting1 LI Juan1 LAN Xia1 HU Qiongying2. Study on the prognostic value of peripheral blood lymphocyte-to-monocyte ratio in multiple myeloma treated by new agents[J]. 中国医药导报, 2020, 17(23): 82-85.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I23/82

[1] Hungria VTM，Crusoé EQ，Bittencourt RI，et al. New proteasome inhibitors in the treatment of multiple myeloma [J]. Hematol Transfus Cell Ther，2019，41（1）：76-83.
[2] Rajkumar SV. Multiple myeloma：2016 update on diagnosis，risk-stratification，and management [J]. Am J Hematol，2016，91（7）：719-734.
[3] Chinese Hematology Association，Chinese Society of Hematology，Chinese Myeloma Committee-Chinese Hematology Association. The guidelines for the diagnosis and management of multiple myeloma in China（2020 revision） [J]. Zhonghua Nei Ke Za Zhi，2020，59（5）：341-346.
[4] Li J，Huang BH. The important role of autologous stem cell transplantation in multiple myeloma [J]. Zhonghua Nei Ke Za Zhi，2020，59（5）：334-338.
[5] Cho H，Yoon DH，Lee JB，et al. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy [J]. Am J Hematol，2017，92（12）：1280-1286.
[6] Zhang Y，Chen XL，Chen WM，et al. Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma [J]. Biomed Res Int，2019：2019：5652935.
[7] Tan D，Fu Y，Tong W，et al. Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer：A meta-analysis [J]. Int J Surg，2018，55：128-138.
[8] Xia LJ，Li W，Zhai JC，et al. Significance of neutrophil-to-lymphocyte ratio，platelet-to-lymphocyte ratio，lymphocyte-to-monocyte ratio and prognostic nutritional index for predicting clinical outcomes in T1-2 rectal cancer [J]. BMC Cancer，2020，20（1）：208.
[9] Liang HG，Gao K，Jia R，et al. Prognostic significance of the combination of preoperative fibrinogen and the neutrophil-lymphocyte ratio in patients with non-small cell lung cancer following surgical resection [J]. Oncol Lett，2019，17（2）：1435-1444.
[10] Huang W，Wang S，Zhang H，et al. Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer [J]. Cancer Biol Med，2018，15（1）：88-96.
[11] Pan YC，Jia ZF，Cao DH，et al. Preoperative lymphocyte-to-monocyte ratio （LMR） could independently predict overall survival of resectable gastric cancer patients [J]. Medicine（Baltimore），2018，97（52）：e13896.
[12] Feng F，Zheng G，Wang Q，et al. Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer [J]. BMC Gastroenterol，2018，18（1）：148.
[13] Ji H，Niu X，Yin L，et al. Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma [J]. Cell Physiol Biochem，2018，45（3）：951-961.
[14] Zhang S，Li M，Yuan F，et al. The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma [J]. Cancer Cell Int，2019：19：272.
[15] Dogan A，Demircioglu S. Assessment of the Neutrophil-Lymphocyte Ratio in Classic Hodgkin Lymphoma Patients [J]. Pak J Med Sci，2019：35（5）：1270-1275.
[16] Jia T，Zhang R，Zhu HY，et al. Prognostic significance of peripheral blood absolute monocyte count and lymphocyte to monocyte ratio in anaplastic large cell lymphoma [J]. Cancer Biomark，2018，22（4）：807-813.
[17] Dosani T，Covut F，Beck R，et al. Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma [J]. Blood Cancer J，2017，7（6）：e579.
[18] Rajkumar SV，Dimopoulos MA，Palumbo A，et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma [J]. Lancet Oncol，2014， 15（12）：e538-e548.
[19] 傅琤琤，金松，吴德沛.《中国多发性骨髓瘤诊治指南（2017年修订）》初始治疗部分的解读[J].中华内科杂志，2017：11：798-799.
[20] Rodríguez-Otero P，Paiva B，Engelhardt M，et al. Is immunotherapy here to stay in multiple myeloma? [J] Haematologica，2017，102（3）：423-432.
[21] Podar K，Jager D.Targeting the Immune Niche within the Bone Marrow Microenvironment：The Rise of Immunotherapy in Multiple Myeloma [J]. Curr Cancer Drug Targets，2017，17（9）：782-805.
[22] Pang YB，Fan LX，Tian MJ，et al. Lymphocyte Count before First Consolidation Therapy Is A Predictor of Relapse free Survival in Acute Myeloid Leukemia [J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi，2018：26（4）：993-998.
[23] Sweiss K，Lee J，Mahmud N，et al. Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant. [J]. Bone Marrow Transplant，2020，55（1）：199-206.
[24] Romano A，Laura Parrinello N，Cerchione C，et al. The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents [J]. Blood Cancer J，2017，7（12）：649.